V. Bozionelou

发表

A Dose Escalation Study of the Biweekly Administration of Paclitaxel, Oxaliplatin and Capecitabine in Patients with Advanced Solid Tumors

D. Mavroudis, V. Georgoulias, A. Kalykaki, 2007, Oncology.

A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2010, Anticancer research.

Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study

M. Falagas, G. Samonis, D. Karageorgopoulos, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib

K. Koutsoukos, H. Kalofonos, A. Bamias, 2017, OncoTargets and therapy.

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2016, Clinical genitourinary cancer.

Systemic Chemotherapy in Urothelial Cancer Introduction

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2022 .

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

D. Mavroudis, V. Georgoulias, A. Kalykaki, 2011, Cancer Chemotherapy and Pharmacology.

Dedifferentiated Paratesticular Liposarcoma with Osseous Metaplasia

M. Papadakis, C. Mamoulakis, I. Heretis, 2015, Case reports in urology.

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer

D. Mavroudis, V. Georgoulias, S. Agelaki, 2009, Cancer Chemotherapy and Pharmacology.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

V. Georgoulias, A. Kalykaki, D. Mavroudis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial

D. Mavroudis, V. Georgoulias, A. Polyzos, 2011, Cancer Chemotherapy and Pharmacology.

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

M. Dimopoulos, A. Papatsoris, G. Aravantinos, 2018, Expert review of pharmacoeconomics & outcomes research.

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

K. Syrigos, V. Georgoulias, N. Ziras, 2012, Cancer Chemotherapy and Pharmacology.

Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study

M. Falagas, G. Samonis, D. Karageorgopoulos, 2012, European Journal of Clinical Microbiology & Infectious Diseases.